Ian Catchpole has been appointed chief scientific officer at France-based Horama SA, which is developing gene therapies to treat rare ophthalmic diseases. Dr Catchpole previously worked for more than 25 years at GlaxoSmithKline Plc where he managing a wide range of scientific, business and strategic projects. His expertise includes ophthalmology, cell and gene therapy, vaccination and immuno-oncology. Dr Catchpole holds a D. Phil in molecular biology and a BA (Hons) in biochemistry from Oxford University.
Horama announced the appointment on 4 May 2020.
Copyright 2020 Evernow Publishing Ltd.